Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD 74.5 million) in a Series A financing round. The funding was led by 5Y Capital, with participation from Gaorong Capital, Neumann Capital, Xiang He Capital, GL Ventures, and Qingzhi Capital. The proceeds will be utilized to enhance AI-driven new drug development, expand team and business operations, upgrade high-performance computational capabilities, and advance the company’s product pipeline through both in-house development and partnerships.
Company Mission and Technology
Founded in 2021, Helixon is committed to constructing a next-generation AI scientific computing platform. By integrating self-developed high-throughput biological experimental technologies, the company offers drug developers intelligent systems for microscopic molecular computing, simulation, and design. Helixon is pioneering the development of efficient machine learning algorithms and data acquisition technologies to revolutionize the drug development process, particularly in the area of macromolecular drug discovery.-Fineline Info & Tech
